| Data: |
2024 |
| Resum: |
Background: Suboptimal response to ursodeoxycholic acid occurs in 40% of primary biliary cholangitis (PBC) patients, affecting survival. Achieving a deep response (normalisation of alkaline phosphatase [ALP] and bilirubin ≤0. 6 upper limit of normal) improves survival. Yet, the long-term effectiveness of second-line treatments remains uncertain. Aims: To evaluate the long-term effectiveness of obeticholic acid (OCA) ± fibrates. Focusing on biochemical response (ALP ≤1. 67 times the upper limit of normal, with a decrease of at least 15% from baseline and normal bilirubin levels), normalisation of ALP, deep response and biochemical remission (deep response plus aminotransferase normalisation). Methods: We conducted a longitudinal, observational, multicentre study involving ursodeoxyccholic acid non-responsive PBC patients (Paris-II criteria) from Spain and Portugal who received OCA ± fibrates. Results: Of 255 patients, median follow-up was 35. 1 months (IQR: 20. 2-53). The biochemical response in the whole cohort was 47. 2%, 61. 4% and 68. 6% at 12, 24 and 36 months. GLOBE-PBC and 5-year UK-PBC scores improved (p < 0. 001). Triple therapy (ursodeoxycholic acid plus OCA plus fibrates) had significantly higher response rates than dual therapy (p = 0. 001), including ALP normalisation, deep response and biochemical remission (p < 0. 001). In multivariate analysis, triple therapy remained independently associated with biochemical response (p = 0. 024), alkaline phosphatase normalisation, deep response and biochemical remission (p < 0. 001). Adverse effects occurred in 41. 2% of cases, leading to 18. 8% discontinuing OCA. Out of 55 patients with cirrhosis, 12 developed decompensation. All with baseline portal hypertension. Conclusion: Triple therapy was superior in achieving therapeutic goals in UDCA-nonresponsive PBC. Decompensation was linked to pre-existing portal hypertension. |
| Nota: |
: EG, EM, MB, MAS, FJ, RMM, JA, AO, MHG, ML and AC: Received fees for consultation and remunerate speeches from Intercept Pharma; CFR: His institution has received grant support from Intercept Pharma\u2010Advanz. JLM, MLGB, MC, IC, JF, PCM, GM, IG, IO, SRT, JP, ER, ShGP, DEG, JMS, DG, LS, LA, AS, JU, MLG and EP\u2010F: Have nothing to disclose. Declaration of personal interests |
| Drets: |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.  |
| Llengua: |
Anglès |
| Document: |
Article ; recerca ; Versió publicada |
| Matèria: |
Adult ;
Aged ;
Alkaline Phosphatase ;
Bilirubin ;
Chenodeoxycholic Acid ;
Cholagogues and Choleretics ;
Drug Therapy, Combination ;
Female ;
Fibric Acids ;
Humans ;
Liver Cirrhosis, Biliary ;
Longitudinal Studies ;
Male ;
Middle Aged ;
Spain ;
Treatment Outcome ;
Ursodeoxycholic Acid |
| Publicat a: |
Alimentary pharmacology & therapeutics, Vol. 59 Núm. 12 (june 2024) , p. 1604-1615, ISSN 1365-2036 |
visitant ::
identificació
(Hospital Universitario de Santiago)
